Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)

NCT00509236 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

129

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
End-Stage Kidney Disease

Interventions

DRUG: Sitagliptin
DRUG: Glipizide

Sponsor

Merck Sharp & Dohme LLC